-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 8th, Gan Lai Pharmaceutical, a wholly-owned subsidiary of Gerry Pharmaceuticals, announced that the liver-targeted prodrug ASC41 oral tablet healthy subjects drug interactions and the pharmacokinetics of non-alcoholic fatty liver disease (NAFLD) patients PK (Phase I clinical trials in the United States) achieved good top-line data
The clinical study consists of two cohorts
Drug interaction data showed that there was no clinically significant difference in the exposure of the active metabolite ASC41-A with or without itraconazole or phenytoin
The study also showed that the pharmacokinetic characteristics of ASC41/ASC41-A were not significantly different between healthy subjects and NAFLD patients
In addition, the pharmacokinetic results of the US study are comparable to those of the ASC41 China Phase I study, indicating that the drug does not have significant pharmacokinetic differences between the Chinese and American populations
Note: The original text has been deleted